Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Soquelitinib in Adults with Hidradenitis Suppurativa
NCT07828860Phase 1Recruiting
- Sponsor
- Corvus Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of soquelitinib in hidradenitis suppurativa (HS), sponsored by Corvus Pharmaceuticals. Primary endpoint: Incidence of adverse events, changes in laboratory values, vital signs, and ECGs. Started Sep 2026; status: recruiting.
02
Drugs
soquelitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07828860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07828860.